Piper Sandler Reiterates Rating on Tenax Therapeutics, Inc. $TENX
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Piper Sandler reiterated its rating on Tenax Therapeutics, Inc. ($TENX) to a "buy" rating in a recent research note and set a price target of $50, a 323.37% upside from the current price.
Tenax Therapeutics, Inc. Stock Up 454.5%
Shares of Tenax Therapeutics, Inc. ($TENX) traded around $11.81 on Saturday, up 454.5% for the day.
Tenax Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Get Tenax Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TENX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.